Material basis and mechanism of action of Arisaematis Rhizoma Preparatum in treatment of chronic obstructive pulmonary disease based on animal experiments, UPLC Q-Exactive Orbitrap MS, and network pharmacology.
10.19540/j.cnki.cjcmm.20240206.301
- Author:
Lin CHU
1
;
Shao-Qing ZHU
2
;
Zi-Xuan YANG
1
;
Wei WANG
1
;
Huan YANG
1
Author Information
1. School of Pharmacy, Jiangsu University Zhenjiang 212013, China.
2. Institute of Medicine and Chemical Engineering, Zhenjiang College Zhenjiang 212028, China.
- Publication Type:Journal Article
- Keywords:
Arisaematis Rhizoma Preparatum;
UPLC Q-Exactive Orbitrap MS;
chronic obstructive pulmonary disease;
network pharmacology;
whole animal experiment
- MeSH:
Animals;
Pulmonary Disease, Chronic Obstructive/metabolism*;
Network Pharmacology;
Mice;
Drugs, Chinese Herbal/administration & dosage*;
Male;
Rhizome/chemistry*;
Humans;
Molecular Docking Simulation;
Chromatography, High Pressure Liquid;
Disease Models, Animal;
Signal Transduction/drug effects*;
Lung/metabolism*;
Phosphatidylinositol 3-Kinases/metabolism*;
Tumor Necrosis Factor-alpha/metabolism*;
Proto-Oncogene Proteins c-akt/metabolism*;
Interleukin-6/immunology*
- From:
China Journal of Chinese Materia Medica
2025;50(7):1792-1802
- CountryChina
- Language:Chinese
-
Abstract:
This study investigates the material basis and mechanism of Arisaematis Rhizoma Preparatum in the treatment of chronic obstructive pulmonary disease(COPD) using animal experiments, component analysis, network pharmacology, and molecular docking. A mouse model of COPD was constructed by cigarette smoke and lipopolysaccharide(LPS). Blood gas analysis was performed to measure the pH and partial pressure of carbon dioxide(PCO_2) in the blood of the mice. Lung tissue sections were analyzed using HE staining, and the effects of Arisaematis Rhizoma Preparatum water extract on inflammatory factors(TNF-α, IL-6, and IL-1β) and the PI3K/AKT signaling pathway in the lung tissue of COPD model mice were studied by qPCR and Western blot. The composition of the Arisaematis Rhizoma Preparatum water extract was analyzed using UPLC Q-Exactive Orbitrap MS. The SwissTargetPrediction database was used to predict the targets of the chemical components in Arisaematis Rhizoma Preparatum. GeneCards, OMIM, TTD, PharmGKB and DrugBank disease databases were used to screen for COPD targets, and the potential targets of Arisaematis Rhizoma Preparatum in treating COPD were identified. A protein-protein interaction(PPI) network of intersection targets was constructed and analyzed using the STRING database and Cytoscape 3.9.0, and core genes were screened. GO functional analysis and KEGG pathway enrichment analysis were performed using R language, and molecular docking verification was conducted using AutoDock Vina software. The results of the animal experiments showed that Arisaematis Rhizoma Preparatum water extract improved pulmonary ventilation function in COPD model mice, reduced lung inflammatory cells, decreased alveolar cavities, and improved lung tissue condition. The levels of inflammatory factors TNF-α, IL-6 and IL-1β were decreased, and the phosphorylation levels of PI3K and AKT were inhibited. Fifty-two chemical components were identified from Arisaematis Rhizoma Preparatum, and 440 intersection targets related to COPD were found. Nine key components were screened, including hydroxyphenylethylamine, L-tyrosine, L-tyrosyl-L-alanine, 3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid, methyl azelate, zingerone, 6-gingerol, linoleamide, and linoleoyl ethanolamine. Five core targets were identified, including AKT1, TNF, STAT3, ESR1, and IL1B. The PI3K/AKT pathway was identified as the key pathway for the treatment of COPD with Arisaematis Rhizoma Preparatum. Molecular docking results showed that 75% of the binding energies of key components and core targets were less than-5 kcal·mol~(-1), indicating good binding affinity. In conclusion, Arisaematis Rhizoma Preparatum may improve pulmonary ventilation function, enhance lung pathological morphology, and reduce pulmonary inflammation in COPD model mice by inhibiting the PI3K/AKT signaling pathway and downregulating TNF-α, IL-6, and IL-1β inflammatory factors. The material basis may be associated with L-tyrosyl-L-alanine, 3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid, zingerone and 6-gingerol, and AKT1 and TNF may be the primary targets.
